Evidence map›Paper›PMID 42653432›Full record

ReviewInternational journal of molecular sciences2026

Organoids-on-a-Chip: An Integrating New Technology for Drug Development.

Mengqi He, Yuting Gong, Xinmei Xu, Menglin Hui, Fei Li, Yongjian Ai

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mengqi HeMOE Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
Yuting GongMOE Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
Xinmei XuMOE Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
Menglin HuiMOE Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
Fei LiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210098, China.
Yongjian AiMOE Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.ORCID 0009-0006-5636-8770

Funding

Beijing Natural Science Foundation L256002Beijing Nova Program 202604841266China Postdoctoral Science Foundation Funded Project 2023T160372, 2022M711779, and BX20220160Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences 2024-I2M-3-013 and 2023-I2M-2-001National Key R&D Program of China 2023YFC3504401 and 2022YFA1103403National Natural Science Foundation of China 82574366, 82304442, and 22304099State Key Laboratory of Respiratory Health and Multimorbidity Special Fund 2060204Young Elite Scien-tist Sponsorship Program of the Beijing Association for Science and Technology BYESS2023166 and BYESS2024140
6 · The paper itself

Abstract

Organoids-on-a-chip integrate the three-dimensional structural fidelity of organoids with the dynamic microenvironmental control capabilities of microfluidic technology, providing a transformative preclinical research platform for drug development. This perspective catalogues organoids-on-a-chip systems encompassing liver, heart, tumor, neural, tissue barrier, and multi-organ integration platforms, and elaborates on their distinctive advantages in dynamically simulating the complete in vivo trajectory of drug absorption, distribution, metabolism, target engagement, and toxicological response. The mechanisms of this technology overcome the limitations associated with conventional static culture models, and interspecies disparities are elucidated. Furthermore, the applications of these systems across critical stages of drug development are summarized, including preclinical safety assessment, integrated pharmacokinetic/pharmacodynamic studies, personalized therapeutics, immunotherapy evaluation, and disease molecular mechanisms. Finally, we highlighted the main challenges facing this field and discussed future directions.

Indexed as

Drug DevelopmentLab-On-A-Chip DevicesOrganoidsAnimalsDrug Evaluation, PreclinicalHumansMicrophysiological Systemsdrug assessmentdrug developmentmicrofluidic chip technologymulti-organ integrationorganoids-on-a-chip

Identifiers

PMID42653432
PMCPMC13513409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.